Croda Pharma Breaks Ground on Excipients Manufacturing Facility
The new excipients manufacturing facility is expected to be completed in 2025.
Croda Pharma, a biopharmaceutical excipients, vaccine adjuvants, and lipids provider, recently broke ground on its newest manufacturing facility in Lamar, Pa. The 23,680 ft² excipients facility will manufacture ingredients for drug delivery systems used in novel therapeutic drugs, including mRNA vaccines and gene editing therapies. It will also support production of lipids that are already used in therapeutics and vaccines, as well as “next-generation” therapeutics that are currently being developed, such as lipids for novel cancer treatments. The new facility will begin construction this year and is expected to be completed in 2025.
“There are rare moments that a team can contribute to such a significant betterment of humankind,” said Bradley Cook, vice-president, North American Operations, Croda, in a May 31, 2023, press release. “The on-going collaboration with the Department of Health and Human Services and its premier biomedical countermeasure development agency, BARDA, has afforded Croda and this team the opportunity and we are extremely excited and proud.”
Source: Croda Pharma
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
